Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNTH-2403 in Relapsed / Refractory Osteosarcoma
NCT07357519Phase 2Recruiting
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Feb 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LNTH-2403 in osteosarcoma (OS), sponsored by Lantheus Holdings, Inc.. Started Feb 2026; status: recruiting.
02
Drugs
LNTH-2403
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07357519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357519.